<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00874523</url>
  </required_header>
  <id_info>
    <org_study_id>SPARTA</org_study_id>
    <nct_id>NCT00874523</nct_id>
  </id_info>
  <brief_title>Raltegravir and Atazanavir Dosing Strategy Study</brief_title>
  <acronym>SPARTA</acronym>
  <official_title>A Randomised, Open-label, Cross-over Study to Examine the Pharmacokinetics and Short-term Safety and Efficacy of Two Dosing Strategies of Raltegravir Plus Atazanavir in HIV-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the steady-state pharmacokinetics and short-term efficacy and safety of two dosing&#xD;
      strategies of raltegravir and atazanavir in virologically suppressed HIV-infected adults&#xD;
      receiving atazanavir-containing combination antiretroviral therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current HIV treatment guidelines recommend the construction of combination regimens&#xD;
      comprising a minimum of three agents from at least two drug classes. There are problems with&#xD;
      the current recommendations for although treatments are effective, their success is often&#xD;
      limited by tolerability, adverse effects and the need to take many pills. Antiretroviral&#xD;
      adherence remains vital and regimens should be simplified wherever possible to facilitate&#xD;
      maximal adherence. The recent availability of the potent HIV integrase inhibitor,&#xD;
      raltegravir, provides an opportunity to explore moves away from current regimen components.&#xD;
      Evidence to support the use of novel regimens must be generated through adequately powered&#xD;
      randomized clinical trials. However, before such trials can be undertaken, preliminary data&#xD;
      to define the pharmacokinetics, safety and tolerability of these regimens are needed to&#xD;
      minimize unnecessary risk for participants. This eight week study will investigate the&#xD;
      steady-state pharmacokinetics, and short-term safety and efficacy of two dosing strategies&#xD;
      (once and twice daily) of raltegravir plus atazanavir in treatment experienced HIV-infected&#xD;
      adults.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of the mean steady-state atazanavir trough plasma concentrations for once (C24) and twice (C12) daily dosing strategies</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparison of mean steady-state raltegravir trough plasma concentrations for once (C24) and twice (C12) daily dosing</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of steady-state pharmacokinetic profiles of once and twice-daily atazanavir</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of the steady-state pharmacokinetic profiles of once and twice-daily raltegravir</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in fasting lipid and glycaemic parameters</measure>
    <time_frame>weeks 4 and 8 and overall</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in CD4+ T-lymphocyte count</measure>
    <time_frame>weeks 4 and 8 and overall</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in HIV-RNA</measure>
    <time_frame>weeks 4 and 8 and overall</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all adverse events attributable to study treatment</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all serious, grade 3 or 4 clinical adverse events, and any adverse event leading to premature cessation of study treatment</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir plus raltegravir</intervention_name>
    <description>atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Reyataz</other_name>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir plus raltegravir</intervention_name>
    <description>atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Reyataz</other_name>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged â‰¥ 18 years with laboratory evidence of HIV-1 infection&#xD;
&#xD;
          -  currently receiving 3 or more unchanged antiretroviral agents including atazanavir&#xD;
             (with or without ritonavir boosting) for at least 24 weeks prior to study entry&#xD;
&#xD;
          -  plasma HIV RNA less than 50 copies/mL for at least 24 weeks prior to study entry&#xD;
&#xD;
          -  provide written, informed consent.&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  prior clinical/virological failure on a PI-containing regimen&#xD;
&#xD;
          -  no clinical history of primary HIV-1 protease mutations identified in local baseline&#xD;
             genotypic analysis of HIV with interpretation using current IAS-USA Drug Resistance&#xD;
             Mutations in HIV-1&#xD;
&#xD;
          -  women: pregnant, breastfeeding, or not willing to use adequate contraception&#xD;
             (including barrier contraception) if of child-bearing potential&#xD;
&#xD;
          -  laboratory abnormalities at screening:&#xD;
&#xD;
               -  absolute neutrophil count (ANC) &lt; 750 cells/mL&#xD;
&#xD;
               -  haemoglobin less than 8.5 g/dL&#xD;
&#xD;
               -  platelet count less than 50 000 cells/mL&#xD;
&#xD;
               -  AST, ALT &gt; 5 times the upper limit of normal&#xD;
&#xD;
               -  serum bilirubin &gt; 5 times the upper limit of normal&#xD;
&#xD;
          -  chronic active hepatitis B infection defined by presence of serum viral hepatitis B&#xD;
             surface antigen (HBsAg) or HBV DNA-positive&#xD;
&#xD;
          -  any malabsorption syndrome likely to affect drug absorption&#xD;
&#xD;
          -  concurrent therapy with human growth hormone or other immunomodulatory agents&#xD;
&#xD;
          -  concomitant medication contraindicated for use with either atazanavir or raltegravir&#xD;
             therapy&#xD;
&#xD;
          -  any inter-current illness requiring hospitalisation&#xD;
&#xD;
          -  current excessive alcohol or illicit substance use&#xD;
&#xD;
          -  unlikely to be able to remain in follow-up for the protocol-defined period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Cooper, MD DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute, UNSW</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>March 31, 2009</study_first_submitted>
  <study_first_submitted_qc>April 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2009</study_first_posted>
  <last_update_submitted>April 10, 2012</last_update_submitted>
  <last_update_submitted_qc>April 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>raltegravir</keyword>
  <keyword>atazanavir</keyword>
  <keyword>HIV infections</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>antiretroviral agents</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

